A Quantitative Systems Pharmacology (QSP) approach for developing combination immune-oncology therapies can be used to better predict effective drug combinations, especially to more accurately correlate the physiological differences between preclinical models and human patients.
PRINCETON, NJ – June 12, 2019 – Certara’s Simcyp®️ physiologically-based pharmacokinetic (PBPK) modeling and simulation technology was used to demonstrate bioequivalence (BE) for the US Food and Drug Administration (FDA) approval of a complex generic drug on the agency’s abbreviated new drug application (ANDA) pathway.
Certara is contributing to 28 sessions, showcasing modeling by its pharmacometricians, systems pharmacologists, and experts in pharmacoeconomics/health economics outcomes research
June 27, 2019 –This webinar discussed the Simcyp Animal Simulators, and the role they play in developing safer and more effective medications in the human and veterinary drug development arena.
Read this blog profiling the student scholarship winners for the 28th annual meeting for the Population Approach Group in Europe (PAGE).
